^
    1d
    Clinical Study on the Efficacy of Laparoscopic Assisted Open Surgery Through Subclavian Approach for Unilateral Thyroid Cancer (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, Xijing Hospital
    New trial
    1d
    Incidental Thyroid Cancer in Cases With Inflammatory Thyroid Lesion (clinicaltrials.gov)
    P=N/A, N=200, Completed, Minia University
    New trial
    1d
    Environmental Factors and Thyroid Cancer (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Sep 2035 --> Jun 2035 | Trial primary completion date: Sep 2030 --> Jun 2030
    Trial completion date • Trial primary completion date
    1d
    Periostin promotes papillary thyroid carcinoma progression by modulating mTOR/AKT pathway. (PubMed, Transl Cancer Res)
    POSTN expression is associated with tumor progression by regulating AKT/mTOR signaling, which further leads to apoptosis and autophagy. POSTN may also be considered a valuable target for therapeutic strategies in PTC.
    Journal
    |
    POSTN (Periostin)
    1d
    The correlation between fine needle aspiration diagnosis and postoperative histopathological results of pediatric thyroid nodules based on the Bethesda system. (PubMed, Front Endocrinol (Lausanne))
    The Bethesda system provides high diagnostic accuracy for definitive cytological categories in pediatric thyroid nodules. Even indeterminate categories carry elevated malignancy risk, supporting careful surgical consideration and the value of BRAF V600E testing for preoperative risk stratification.
    Retrospective data • Journal
    |
    BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • TERT (Telomerase Reverse Transcriptase) • RAS (Rat Sarcoma Virus)
    |
    BRAF V600E • BRAF V600 • RET fusion • RAS mutation • RET mutation
    1d
    Upregulation of CSDE1 mediated by METTL3 facilitates the progression of papillary thyroid cancer via the Wnt/β-catenin pathway. (PubMed, Endokrynol Pol)
    CSDE1 promotes PTC progression through the Wnt/β-catenin pathway under the regulation of METTL3-mediated m⁶A modification, serving as a promising prognostic biomarker and therapeutic target.
    Journal
    |
    METTL3 (Methyltransferase Like 3)
    1d
    Mechanisms of Yiguanjian Decoction against Thyroid Cancer: A Network-Based Pharmacological Investigation. (PubMed, Chin J Integr Med)
    This study comprehensively reveals YGJ's pharmacological properties against thyroid cancer, identifying its core targets and multi-pathway mechanisms.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MAPK1 (Mitogen-activated protein kinase 1) • MAPK14 (Mitogen-Activated Protein Kinase 14) • MAPK3 (Mitogen-Activated Protein Kinase 3) • RELA (RELA Proto-Oncogene)
    1d
    3D radiomics profiling of thyroid tumors using micro-CT. (PubMed, Sci Rep)
    Exploratory analysis in a limited TERT cohort (8 mutated vs 103 wild-type) identified prospective radiomics patterns associated with TERT promoter mutations, suggesting potential surrogate imaging biomarkers that warrant further investigation. Micro-CT radiomics shows promise as a complementary tool for diagnostic classification in thyroid cancer and offers a platform for quantitative 3D tissue characterization pending broader validation.
    Journal
    |
    BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
    |
    BRAF V600E • BRAF V600
    1d
    Combined epigenomic landscapes of 5mC, 5hmC, and 6mA modifications in papillary thyroid carcinogenesis. (PubMed, Commun Biol)
    Co-expression network analysis highlighted disrupted transcriptional coordination in tumors. This work establishes a multidimensional epigenetic framework for PTC with combinatorial diagnostic signatures and condition-specific associations between DNA modifications and driver mutations (BRAF vs. RAS).
    Journal
    |
    BRAF (B-raf proto-oncogene) • RAS (Rat Sarcoma Virus)
    |
    BRAF mutation • RAS mutation
    2d
    The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response (clinicaltrials.gov)
    P4, N=48, Recruiting, University Hospital Dubrava | Active, not recruiting --> Recruiting | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Enrollment open • Trial completion date • Trial primary completion date
    2d
    Diagnostic value of the nomogram model based on multimodal ultrasound features combined with PS-Tg for differentiating benign and malignant thyroid nodules. (PubMed, Gland Surg)
    The calibration of the nomogram was good, showing no significant deviation (χ2=4.43, P=0.816). The nomogram based on the multivariate logistic regression model incorporating multimodal ultrasound features combined with PS-Tg demonstrates high diagnostic value in differentiating benign and malignant thyroid nodules.
    Journal
    |
    TG (Thyroglobulin)
    2d
    Development and validation of a machine learning model integrating spectral computed tomography-derived three‑dimensional quantitative parameters and clinical features for predicting minimal extrathyroidal extension in papillary thyroid microcarcinoma. (PubMed, Gland Surg)
    ML models that incorporate spectral CT 3D parameters and clinical features offer a promising approach for preoperative prediction of mETE in PTMC. Following external validation in multicenter cohorts, these models may serve as adjunctive tools to inform clinical decision-making and risk stratification.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600